Tendinopathy: Disorders that are causes by overuse of tendons.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
157 |
4. Check minimum number of eventsNone |
157 |
5. Include endpointsNone |
157 |
6. Filter based on genotype QC (FinnGen only) |
157 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M76
- Name in latin
- Tendinitis musculi psoae
Similar endpoints
↥List of similar endpoints to
Psoas tendinitis
based on the number of shared cases.
Similar with more cases:
- Enthesopathies of lower limb, excluding foot
- Soft tissue disorders
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 827 | 506 | 319 |
| Only index persons | 808 | 498 | 310 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 48.04 | 49.29 | 46.15 |
| Only index persons | 47.94 | 49.19 | 45.94 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 157 | 109 | 48 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | 55.06 | 54.40 | 56.55 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 136
- Matched controls
- 1359
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M76.1
ICD-10 Finland
Psoas tendinitis
+∞
196.4
136
*
NF1AA
NOMESCO Finland
Hip X-ray examination
15.5
22.6
38
33
NE1BG
NOMESCO Finland
Pelvic, hip and femur MRI examination with high intensity magnet
30.2
20.5
27
11
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
81.9
19.3
21
*
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
36.0
19.1
24
8
M16.1
ICD-10 Finland
Other primary coxarthrosis
10.0
19.0
40
54
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
39.1
18.7
23
7
M76.0
ICD-10 Finland
Gluteal tendinitis
205.5
18.0
18
*
NFF25
NOMESCO Finland
Cleaning of hip joint, arthroscopic
179.7
15.8
16
*
L13
ICPC
Hip symptom/complaint
6.4
15.3
44
94
M48.0
ICD-10 Finland
Spinal stenosis
64.1
15.2
17
*
M01AH05
ATC
etoricoxib; oral
4.2
13.1
101
554
NE1AA
NOMESCO Finland
Pelvis X-ray examination
15.4
12.4
20
15
N02AX02
ATC
tramadol; systemic, rectal
3.9
12.3
71
300
M54.9
ICD-10 Finland
Dorsalgia, unspecified
10.8
12.1
23
25
N03AX16
ATC
pregabalin; oral
4.9
12.0
43
116
M79.6
ICD-10 Finland
Pain in limb
3.8
11.8
68
283
M16.0
ICD-10 Finland
Primary coxarthrosis, bilateral
9.5
11.7
24
30
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
27.8
11.4
15
6
A02BC02
ATC
pantoprazole; systemic
3.8
11.3
104
623
NFG00
NOMESCO Finland
Arthroplasty of hip joint
+∞
10.5
10
*
NJ3NA
NOMESCO Finland
Measurement of difference in extremity lengty with X-ray
28.4
10.0
13
5
M54.5
ICD-10 Finland
Low back pain
3.8
9.8
48
171
A02BC05
ATC
esomeprazole; systemic
3.3
9.7
70
334
XX2AT
NOMESCO Finland
Other injection with ultrasound examination
19.3
9.6
14
8
Q65.88
ICD-10 Finland
Other congenital deformities of hip
+∞
9.5
9
*
N06AX21
ATC
duloxetine; oral
5.8
9.3
27
56
M75.1
ICD-10 Finland
Rotator cuff syndrome
3.8
9.2
44
152
M54.4
ICD-10 Finland
Lumbago with sciatica
6.1
9.2
25
48
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.2
9.1
64
297
N03AX12
ATC
gabapentin; oral
5.5
8.7
26
56
NFL30
NOMESCO Finland
Transposition of muscle of hip or thigh
29.6
8.6
11
*
M25.5
ICD-10 Finland
Pain in joint
3.2
8.6
57
250
NK5AT
NOMESCO Finland
Joint injection with ultrasound guidance not elsewhere classified
+∞
8.4
8
*
NFE15
NOMESCO Finland
Plastic repair of capsule or ligament of hip joint
+∞
8.4
8
*
NFB30
NOMESCO Finland
Primary total prosthetic replacement of hip joint not using cement
6.7
8.4
21
36
M01AB55
ATC
diclofenac, combinations; oral
10.4
8.0
15
16
L89
ICPC
Osteoarthrosis of hip
16.3
7.9
12
8
M03BX02
ATC
tizanidine; oral
2.9
7.8
97
624
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
26.7
7.7
10
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.1
7.6
48
201
M70.6
ICD-10 Finland
Trochanteric bursitis
4.4
7.4
27
72
M01AE02
ATC
naproxen; oral, rectal
2.7
7.3
89
557
M16.3
ICD-10 Finland
Other dysplastic coxarthrosis
31.8
7.2
9
*
NF1DA
NOMESCO Finland
X-ray of hips
17.8
6.9
10
6
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
5.8
6.6
18
35
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.6
6.5
67
372
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
73.1
6.5
7
*
N02BE01
ATC
paracetamol; systemic, rectal
3.6
6.5
122
959
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
4.7
6.4
21
51
N02AJ06
ATC
codeine and paracetamol; systemic
2.6
6.3
56
284
J01DB01
ATC
cefalexin; oral
3.2
6.3
118
910
M16
ICD-10 Finland
Coxarthrosis [arthrosis of hip]
7.3
6.2
14
21
UDQ12
NOMESCO Finland
Flexible laryngoscopy
7.3
6.2
14
21
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.9
6.0
40
171
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
76
356
3.20
11.60
2.4
2.2
52.1
55.5
u/l
0.57
71
331
83
435
2.93
10.00
3.4
3.0
19.1
38.5
ng/l
1.14
46
271
60
272
2.95
9.32
2.7
2.0
—
—
—
0
0
137
989
4.02
8.70
4.8
3.8
14.7
14.6
pmol/l
0.22
126
900
96
575
2.72
8.50
3.7
3.5
—
—
—
0
0
130
950
3.14
7.21
7.1
6.9
69.2
77.0
u/l
3.27
125
889
47
216
2.68
6.85
1.6
1.2
16.1
32.2
iu/ml
1.24
19
76
45
205
2.68
6.65
1.4
1.3
18.0
6.2
u/ml
0.32
21
79
89
561
2.35
6.43
7.8
6.6
1.2
1.2
mmol/l
0.74
78
484
37
157
2.77
6.24
4.4
4.0
34.0
33.3
%
0.11
26
100
104
709
2.38
6.16
6.7
9.7
3.8
4.0
e9/l
0.47
85
628
54
292
2.29
5.40
2.6
3.0
897.0
867.5
ng/l
0.03
46
251
52
277
2.31
5.38
3.1
2.7
339.8
5112.4
umol/l
1.32
46
250
88
581
2.17
5.34
4.3
3.3
0.0
0.0
estimate
0.50
12
116
87
574
2.16
5.27
4.3
3.3
0.0
0.0
estimate
0.00
12
117
149
1292
4.01
5.06
18.2
11.0
19.5
22.4
mg/l
0.51
133
976
72
447
2.13
5.05
1.8
1.8
109.8
99.4
pmol/l
1.02
35
227
145
1212
3.57
4.79
6.1
4.5
1.7
2.9
mu/l
0.63
134
1104
86
580
2.07
4.75
6.9
4.6
0.0
0.0
estimate
0.50
11
121
75
503
1.94
4.01
6.5
5.2
1.2
1.2
mmol/l
1.26
64
457
95
694
1.93
3.89
3.9
4.0
6.2
6.7
mmol/l
1.71
88
631
72
489
1.87
3.61
2.1
2.2
81.6
74.8
nmol/l
1.28
65
437
145
1261
2.96
3.48
5.1
4.1
5.8
5.9
mmol/l
0.79
132
1150
113
894
1.94
3.43
3.1
2.7
36.7
43.5
u/l
0.85
106
846
44
259
1.97
3.35
2.5
1.9
2.4
3.2
mg/l
2.28
37
222
112
888
1.91
3.32
2.9
3.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
7
8.85
3.29
1.0
1.3
—
—
—
0
0
68
464
1.82
3.28
4.5
3.4
—
—
—
0
0
8
16
5.21
3.09
1.8
1.3
—
—
—
0
0
23
111
2.26
2.90
1.7
1.9
331.3
393.3
nmol/l
0.81
23
103
5
6
8.55
2.77
1.0
1.2
—
—
—
0
0
152
1405
3.57
2.75
11.9
9.0
23.8
25.7
u/l
1.21
147
1355
31
174
1.97
2.67
1.6
1.6
1133.5
1139.1
nmol/l
0.01
21
127
142
1258
2.35
2.63
16.1
10.2
81.6
85.6
ml/min/173m2
1.34
118
1011
17
76
2.39
2.55
2.7
2.3
0.0
0.1
e6/l
1.45
17
70
9
26
3.61
2.52
1.4
1.2
—
—
—
0
0
31
179
1.91
2.46
3.5
2.5
4.2
3.9
e6/l
0.05
18
97
40
252
1.79
2.42
1.6
1.5
0.7
1.0
mg/l
0.90
31
193
5
8
6.41
2.39
1.0
1.3
—
—
—
0
0
140
1245
2.15
2.37
4.2
3.7
1.3
1.3
mmol/l
0.14
128
1148
44
288
1.73
2.33
1.4
1.2
0.8
0.8
u/ml
0.00
13
77
56
392
1.67
2.32
4.4
2.8
—
—
—
0
0
7
18
4.02
2.28
1.4
1.4
—
—
—
0
0
145
1315
2.34
2.19
5.2
4.5
2.9
2.8
mmol/l
0.61
132
1219
42
278
1.70
2.12
1.9
1.5
—
—
—
0
0
8
25
3.31
2.12
2.3
1.5
54.8
30.3
nmol/l
—
8
25
143
1295
2.17
2.08
4.5
4.1
4.9
4.7
mmol/l
0.90
131
1206
6
15
4.11
2.06
1.0
1.1
—
—
—
0
0
30
184
1.78
1.97
3.2
2.3
1.3
1.2
e6/l
0.16
17
99
142
1290
2.05
1.93
4.8
4.0
1.5
1.5
mmol/l
0.05
130
1192
132
1177
1.76
1.84
6.7
5.3
38.8
39.5
mmol/mol
0.41
122
1091
5
12
4.26
1.83
1.6
1.2
—
—
—
0
0
5
12
4.26
1.83
1.6
1.2
—
—
—
0
0
27
164
1.78
1.83
1.7
2.0
—
—
—
0
0
24
142
1.81
1.77
1.7
1.8
—
—
—
0
0
9
36
2.59
1.77
1.9
1.6
—
—
—
0
0
5
13
3.93
1.73
1.0
1.0
—
—
—
0
0
10
44
2.36
1.56
2.4
1.5
—
—
—
0
0
5
15
3.41
1.53
1.0
1.1
—
—
—
0
0
62
486
1.46
1.45
4.6
3.9
36.4
36.3
g/l
0.06
55
457
42
307
1.50
1.38
3.5
3.4
0.0
0.0
estimate
0.68
12
120
5
17
3.00
1.37
2.4
1.6
—
—
—
0
0
5
17
3.00
1.37
2.4
1.6
—
—
—
0
0
5
17
3.00
1.37
1.4
1.5
—
—
—
0
0
5
17
3.00
1.37
2.4
1.6
—
—
—
0
0
5
17
3.00
1.37
2.4
1.6
—
—
—
0
0
11
54
2.12
1.36
3.1
2.1
0.9
1.3
%
0.94
11
54
5
18
2.83
1.29
2.4
1.6
—
—
—
0
0
5
18
2.83
1.29
2.4
1.6
—
—
—
0
0
32
226
1.52
1.23
1.8
1.7
429.4
439.1
pmol/l
0.08
27
191
6
26
2.36
1.20
2.2
1.6
—
—
—
0
0
10
50
2.07
1.19
6.2
2.9
39.8
48.6
%
—
10
50
15
89
1.76
1.12
1.3
1.2
227.5
175.6
iu/ml
—
6
38
19
121
1.65
1.12
3.7
4.6
2.1
42.6
ug/l
0.57
14
95
5
21
2.42
1.10
1.4
1.4
—
—
—
0
0
7
32
2.24
1.09
1.4
1.4
—
—
—
0
0
13
75
1.80
1.06
1.4
2.5
17.2
75.4
u/ml
1.06
13
70
39
296
1.42
1.05
4.1
2.6
0.3
0.5
e6/l
0.60
28
212
5
22
2.31
1.04
1.6
1.1
—
—
—
0
0
9
48
1.93
1.02
1.4
1.8
—
—
—
0
0
5
23
2.21
0.98
1.0
1.3
—
—
—
0
0
9
50
1.85
0.98
1.2
2.0
—
—
—
0
0
9
50
1.85
0.98
4.6
7.0
24.0
25.2
mmol/l
—
9
50
10
57
1.81
0.86
3.3
3.8
5.3
5.6
kpa
—
10
52
6
33
1.85
0.80
1.3
1.2
—
—
—
0
0
20
141
1.48
0.79
2.6
6.5
—
—
—
0
0
131
1230
1.39
0.78
18.1
12.0
40.1
39.9
%
0.10
94
956
5
24
2.12
0.75
1.8
1.4
—
12.5
—
0
5
7
38
1.88
0.74
4.0
3.9
25.4
26.2
mmol/l
—
7
38
22
161
1.43
0.73
1.8
1.6
30.5
29.5
s
0.33
22
156
30
234
1.35
0.70
3.7
3.6
25.3
21.0
%
0.74
13
108
10
63
1.63
0.63
2.1
1.4
—
—
—
0
0
8
49
1.67
0.63
1.6
1.4
—
—
—
0
0
26
202
1.34
0.62
4.4
3.0
18.6
430.0
ng/l
0.72
16
143
12
80
1.54
0.62
2.9
1.5
—
—
—
0
0
0
20
0.00
0.61
0.0
1.7
—
—
—
0
0
0
22
0.00
0.60
0.0
1.7
—
—
—
0
0
0
23
0.00
0.59
0.0
1.7
—
—
—
0
0
106
1128
0.81
0.53
23.8
13.9
13.8
13.6
%
0.18
106
1108
9
63
1.45
0.53
1.2
1.2
—
—
—
0
0
13
92
1.45
0.52
1.0
3.3
90.2
66.7
ml/min/173m2
—
6
35
21
165
1.31
0.48
3.4
2.8
1.0
0.7
ug/l
0.30
11
107
11
78
1.44
0.44
1.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
5
34
1.49
0.40
2.0
2.4
—
—
—
0
0
5
35
1.44
0.39
1.4
1.1
—
—
—
0
0
5
35
1.44
0.39
1.4
1.1
—
—
—
0
0
5
78
0.63
0.36
3.6
2.3
172.2
82.7
ng/l
—
5
71
45
401
1.17
0.35
3.1
3.2
2.3
2.4
mmol/l
0.16
39
358
29
250
1.20
0.32
1.4
1.5
—
—
—
0
0
21
176
1.22
0.31
1.8
1.8
—
—
—
0
0
5
37
1.36
0.24
1.2
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
14.0
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
7
62
1.13
0.17
1.4
1.3
—
—
—
0
0
12
141
0.84
0.17
1.5
1.6
—
—
—
0
0
13
114
1.15
0.12
2.0
1.7
—
—
—
0
0
5
44
1.14
0.10
3.0
2.0
—
—
—
0
0
10
114
0.87
0.10
4.3
2.9
—
—
—
0
0
13
117
1.12
0.08
2.1
1.8
—
—
—
0
0
11
98
1.13
0.08
2.3
1.9
—
—
—
0
0
12
108
1.12
0.07
2.3
1.9
0.2
0.2
g/l
0.46
12
100
8
78
1.03
0.07
2.1
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
7
0.00
0.00
0.0
1.0
—
134.4
—
0
7
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
8
0.00
0.00
0.0
2.4
—
112.6
—
0
8
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_PSOASTEND and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have M13_PSOASTEND.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: M13_PSOASTEND – Psoas tendinitis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data